CNS Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense
CNS Pharmaceuticals, Inc. (CNSP) reported Increase (Decrease) in Prepaid Expense of -$1.13 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2022-11-10
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2022-09-30 was -$875.53K.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2022-06-30 was $58.83K, a 96.58% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2022-03-31 was -$318.12K, a 360.40% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2021-12-31 was $147.02K.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2021 was $1.52M, a 373.09% increase from fiscal 2020.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2020 was $321.35K, a 48.14% decline from fiscal 2019.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2019 was $619.62K.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2018 was -$18.65K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$875.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$816.70K derived: sum of 2 quarters · filed 2022-11-10 | -$1.13M 10-Q · filed 2022-11-10 | -$987.80K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $58.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$259.30K 10-Q · filed 2022-08-12 | -$112.27K derived: sum of 3 quarters · filed 2022-08-12 | -$578.82K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | -$318.12K 10-Q · filed 2022-05-13 | -$171.10K derived: sum of 2 quarters · filed 2022-05-13 | -$637.64K derived: sum of 3 quarters · filed 2022-11-10 | $1.08M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | $147.02K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$319.52K derived: sum of 2 quarters · filed 2022-11-10 | $1.40M derived: sum of 3 quarters · filed 2022-11-10 | $1.52M 10-K · filed 2022-03-03 |
| 2021-09-30 | -$466.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.25M derived: sum of 2 quarters · filed 2022-11-10 | $1.37M 10-Q · filed 2022-11-10 | $1.14M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.84M 10-Q · filed 2022-08-12 | $1.60M derived: sum of 3 quarters · filed 2022-08-12 | $1.49M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $122.17K 10-Q · filed 2022-05-13 | -$112.94K derived: sum of 2 quarters · filed 2022-05-13 | -$232.58K derived: sum of 3 quarters · filed 2022-05-13 | $287.40K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$235.10K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$354.75K derived: sum of 2 quarters · filed 2022-03-03 | $165.23K derived: sum of 3 quarters · filed 2022-03-03 | $321.35K 10-K · filed 2022-03-03 |
| 2020-09-30 | -$119.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $400.33K derived: sum of 2 quarters · filed 2021-11-12 | $556.46K 10-Q · filed 2021-11-12 | $752.72K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $519.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $676.10K 10-Q · filed 2021-08-13 | $872.37K derived: sum of 3 quarters · filed 2021-08-13 | $907.35K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $156.12K 10-Q · filed 2021-05-13 | $352.39K derived: sum of 2 quarters · filed 2021-05-13 | $387.38K derived: sum of 3 quarters · filed 2021-05-13 | $788.75K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $196.27K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $231.25K derived: sum of 2 quarters · filed 2021-02-12 | $632.62K derived: sum of 3 quarters · filed 2021-02-12 | $619.62K 10-K · filed 2021-02-12 |
| 2019-09-30 | $34.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $436.36K derived: sum of 2 quarters · filed 2020-11-12 | $423.36K 10-Q · filed 2020-11-12 | $456.36K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $401.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $388.37K 10-Q · filed 2020-08-10 | $421.37K derived: sum of 3 quarters · filed 2020-08-10 | |
| 2019-03-31 | -$13.00K 10-Q · filed 2020-05-15 | $20.00K derived: sum of 2 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$18.65K 10-K · filed 2020-03-12 | ||
| 2018-09-30 | -$51.65K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |